title: [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
abstract: Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis. To improve the poor outcome, adjuvant chemotherapy is indispensable for advanced cases with a high relapse risk after standard definitive treatments including surgery and/or radiotherapy. To define an adequate administration schedule in adjuvant chemotherapy with S-1, a controlled randomized study in multi-institutes was done. The results showed the 2-week administration followed by 1-week rest was superior to the 4-week administration followed by the 2-week rest in terms of safety and efficacy. In the present paper, some problems of adjuvant chemotherapy were discussed, and the protocol was described in terms of a multi-institutional controlled randomized comparison study of S-1 versus UFT in an adjuvant chemotherapy setting for locally advanced HNSCC.
authors.affiliation: Dept. of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Japan.
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishitoya
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Hideaki
authors.initials: H
authors.lastname: Katori
authors.forename: Choichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Gabor
authors.initials: G
authors.lastname: Toth
mesh_terms: D000855:Anorexia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D015337:Multicenter Studies as Topic; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid